CorMedix (CRMD) is a buy with its financial turnaround, robust growth, and first-mover advantage in the US dialysis market.

The Caixin China General Services PMI rose to 51.1 in May 2025, up from April’s seven-month low of 50.7 and in line with ...

Metallus is poised for growth amid Trump's steel tariffs and defense orders. Shares are quite undervalued, trading at low ...

Natural Resource Partners has strong profitability and a low P/E ratio. NRP stock remains exposed to macroeconomic and sector ...